Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02512757 · ClinicalTrials.gov registry record
A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology
A clinical trial, sponsored by Innovis.
- Completed
- Registry status
- 150
- Enrollment target
NCT02512757: Completed study, sponsored by Innovis.
NCT02512757 is a clinical trial that has completed, run by Innovis. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02512757 has completed, sponsored by Innovis.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
This is a prospective, multi-center study to evaluate the diagnostic performance characteristics of the AminoIndex™ technology among patients at high risk for developing lung cancer as compared with standard lung cancer screening and diagnostic procedures including low-dose CT, high-dose CT, biopsy and histopathology.
Primary Outcome
To evaluate the diagnostic performance characteristics of the AminoIndex™ technology among patients at high risk for developing lung cancer as compared with standard lung cancer screening and diagnostic procedures including low-dose CT, high-dose CT, biopsy and histopathology.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2015-08-13 |
| Est. Completion | 2017-07-17 |
What the finished NCT02512757 record still lists
NCT02512757 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02512757 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02512757 about?
NCT02512757 is a clinical study titled "A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology". This is a prospective, multi-center study to evaluate the diagnostic performance characteristics of the AminoIndex™ technology among patients at high risk for developing lung cancer as compared with standard lung cancer screening and diagnostic procedures including low-dose CT, high-dose CT, biopsy ...
What is the current status of trial NCT02512757?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2015-08-13. Estimated completion is 2017-07-17.
Who is sponsoring clinical trial NCT02512757?
This trial is sponsored by Innovis, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI